Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary - Quiz - MDSpire

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • By

  • Charlotte A. Leseman

  • Alessandro M. Bonomi

  • Job Schuitema

  • Stefano Granieri

  • Margaret Sällberg Chen

  • Ajay V. Maker

  • Zeeshan Ateeb

  • Laura D. Wood

  • Rogier P. Voermans

  • Giovanni Marchegiani

  • Marco Del Chiaro

  • Johannes C. F. Ket

  • Anne Marie Lennon

  • Marc G. Besselink

  • Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

  • 0 min

Share

Original Source(s)

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • by Charlotte A. Leseman, Alessandro M. Bonomi, Job Schuitema, Stefano Granieri, Margaret Sällberg Chen, Ajay V. Maker, Zeeshan Ateeb, Laura D. Wood, Rogier P. Voermans, Giovanni Marchegiani, Marco Del Chiaro, Johannes C. F. Ket, Anne Marie Lennon, Marc G. Besselink, Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

Related Content

Effect of various interventions on relieving non-coring needle puncture-related pain in patients with totally implantable venous access port: a network meta-analysis of randomized control trials

Tumor-driven stabilization of CD8+ T cell exhaustion and implications for cancer immunotherapy

ESMO Breast Cancer 2026 Highlights: TRAK-ER

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min